These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 37229829)

  • 1. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
    Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
    Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in the preclinical and clinical research of proteolysis targeting chimera].
    Liu Z; Liu S
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3615-3627. PubMed ID: 37805842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
    Singh H; Agrawal DK
    Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTACs: past, present and future.
    Li K; Crews CM
    Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in PROTACs for Drug Targeted Protein Research.
    Yao T; Xiao H; Wang H; Xu X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
    Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
    J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACS: A technology with a gold rush-like atmosphere.
    Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
    Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Studies of PROTACs in Hematological Malignancies.
    Fuchs O; Bokorova R
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.